SCHEMBL5136793

SCHEMBL5136793

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1CO)CC1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
HDAC1 Q13547 1/20 0.37
TSHR P16473 5/20 0.37
CCR4 P51679 2/20 0.36
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 4/20 0.36
CYP3A4 P08684 4/20 0.36
HSD17B10 Q99714 4/20 0.36
HPGD P15428 4/20 0.36
BCHE P06276 4/20 0.36
ACHE P22303 1/20 0.36
SLC6A2 P23975 1/20 0.34
ABCC1 P33527 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135330 0.92 C5AR1 (0.43) C5AR1HDAC1TSHRCCR4ALDH1A1
SCHEMBL5136466 0.91 C5AR1 (0.42) C5AR1HDAC1TSHRCCR4ALDH1A1
SCHEMBL651501 0.90 C5AR1 (0.44) C5AR1HDAC1TSHRALDH1A1KDM4E
SCHEMBL5134718 0.89 C5AR1 (0.43) C5AR1HDAC1TSHRALDH1A1KDM4E
SCHEMBL5136106 0.89 C5AR1 (0.41) C5AR1HDAC1TSHRCCR4ALDH1A1
SCHEMBL5135152 0.89 C5AR1 (0.41) C5AR1HDAC1TSHRCCR4ALDH1A1
SCHEMBL5137310 0.89 C5AR1 (0.41) C5AR1HDAC1TSHRCCR4ALDH1A1
SCHEMBL5137864 0.88 C5AR1 (0.44) C5AR1HDAC1TSHRALDH1A1KDM4E
SCHEMBL5137300 0.88 CCR4 (0.49) C5AR1HDAC1TSHRCCR4ALDH1A1
SCHEMBL5137556 0.88 C5AR1 (0.40) C5AR1HDAC1TSHRCCR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed